June 25. Brisbane Australia based diagnostics company Ellume has struck a major deal with the USA’s Delta Airlines for its rapid COVID test, giving the Australian medtech access to up to one million passengers a month travelling with one of the world’s largest airlines.
This is the first agreement with a commercial airline reached by Ellume and paves the way for the company to ramp up production of its tests in a new US facility later this year.
Ellume’s COVID test, which can identify a positive COVID case in minutes, is the only FDA-approved antigen test for asymptomatic cases that can be verified in just one test.
Under US Centers for Disease Control (CDC), any international passenger arriving in the use must be tested for COVID-19 before being allowed entry. That applies to US citizens returning home.
Ellume recommends travellers in the US acquire two tests for travelling, one before leaving the country and one upon arrival.
The tests are verified by AZOVA, Ellume’s proctoring partner, which provides the certificate to the traveller for presentation to Delta Airlines as required by the CDC.
Ellume is not having the same success in Australia, which Parsons doesn’t see changing any time soon.
Source: Business News Australia